Tags

Type your tag names separated by a space and hit enter

The SARS-CoV-2 Vaccine Pipeline: an Overview.
Curr Trop Med Rep. 2020; 7(2):61-64.CT

Abstract

Purpose of Review

The goal of this review is to provide a timely overview on efforts to develop a vaccine for the 2019 novel coronavirus SARS-CoV-2, the causative agent of coronavirus disease (COVID-19).

Recent Findings

Previous research efforts to develop a severe acute respiratory syndrome coronavirus (SARS-CoV) vaccine in the years following the 2003 pandemic have opened the door for investigators to design vaccine concepts and approaches for the COVID-19 epidemic in China. Both SARS-CoV and SARS-CoV-2 exhibit a high degree of genetic similarity and bind to the same host cell ACE2 receptor. Based on previous experience with SARS-CoV vaccines, it is expected that all COVID-19 vaccines will require careful safety evaluations for immunopotentiation that could lead to increased infectivity or eosinophilic infiltration. Besides this, a COVID-19 vaccine target product profile must address vaccinating at-risk human populations including frontline healthcare workers, individuals over the age of 60, and those with underlying and debilitating chronic conditions. Among the vaccine technologies under evaluation are whole virus vaccines, recombinant protein subunit vaccines, and nucleic acid vaccines.

Summary

Each current vaccine strategy has distinct advantages and disadvantages. Therefore, it is paramount that multiple strategies be advanced quickly and then evaluated for safety and efficacy. Ultimately, the safety studies to minimize undesired immunopotentiation will become the most significant bottleneck in terms of time.

Links

PMC Free PDF

Authors+Show Affiliations

Chen WH
Texas Children's Hospital Center for Vaccine Development, Departments of Pediatrics and Molecular Virology & Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX USA.
Strych U
Texas Children's Hospital Center for Vaccine Development, Departments of Pediatrics and Molecular Virology & Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX USA.
Hotez PJ
Texas Children's Hospital Center for Vaccine Development, Departments of Pediatrics and Molecular Virology & Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX USA.
Bottazzi ME
Texas Children's Hospital Center for Vaccine Development, Departments of Pediatrics and Molecular Virology & Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32219057

Citation

Chen, Wen-Hsiang, et al. "The SARS-CoV-2 Vaccine Pipeline: an Overview." Current Tropical Medicine Reports, vol. 7, no. 2, 2020, pp. 61-64.
Chen WH, Strych U, Hotez PJ, et al. The SARS-CoV-2 Vaccine Pipeline: an Overview. Curr Trop Med Rep. 2020;7(2):61-64.
Chen, W. H., Strych, U., Hotez, P. J., & Bottazzi, M. E. (2020). The SARS-CoV-2 Vaccine Pipeline: an Overview. Current Tropical Medicine Reports, 7(2), 61-64. https://doi.org/10.1007/s40475-020-00201-6
Chen WH, et al. The SARS-CoV-2 Vaccine Pipeline: an Overview. Curr Trop Med Rep. 2020;7(2):61-64. PubMed PMID: 32219057.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The SARS-CoV-2 Vaccine Pipeline: an Overview. AU - Chen,Wen-Hsiang, AU - Strych,Ulrich, AU - Hotez,Peter J, AU - Bottazzi,Maria Elena, Y1 - 2020/03/03/ PY - 2020/3/29/pubmed PY - 2020/3/29/medline PY - 2020/3/29/entrez KW - COVID-19 KW - Coronavirus KW - RBD KW - Receptor binding domain KW - Wuhan virus SP - 61 EP - 64 JF - Current tropical medicine reports JO - Curr Trop Med Rep VL - 7 IS - 2 N2 - Purpose of Review: The goal of this review is to provide a timely overview on efforts to develop a vaccine for the 2019 novel coronavirus SARS-CoV-2, the causative agent of coronavirus disease (COVID-19). Recent Findings: Previous research efforts to develop a severe acute respiratory syndrome coronavirus (SARS-CoV) vaccine in the years following the 2003 pandemic have opened the door for investigators to design vaccine concepts and approaches for the COVID-19 epidemic in China. Both SARS-CoV and SARS-CoV-2 exhibit a high degree of genetic similarity and bind to the same host cell ACE2 receptor. Based on previous experience with SARS-CoV vaccines, it is expected that all COVID-19 vaccines will require careful safety evaluations for immunopotentiation that could lead to increased infectivity or eosinophilic infiltration. Besides this, a COVID-19 vaccine target product profile must address vaccinating at-risk human populations including frontline healthcare workers, individuals over the age of 60, and those with underlying and debilitating chronic conditions. Among the vaccine technologies under evaluation are whole virus vaccines, recombinant protein subunit vaccines, and nucleic acid vaccines. Summary: Each current vaccine strategy has distinct advantages and disadvantages. Therefore, it is paramount that multiple strategies be advanced quickly and then evaluated for safety and efficacy. Ultimately, the safety studies to minimize undesired immunopotentiation will become the most significant bottleneck in terms of time. SN - 2196-3045 UR - https://www.unboundmedicine.com/medline/citation/32219057/full_citation DB - PRIME DP - Unbound Medicine ER -